(Q27852650)
Statements
1 reference
Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement (English)
1 reference
January 2014
0 references
83
0 references
1
0 references
109-11
0 references